Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.